SONIRE Therapeutics
sonire-therapeutics.com
Actively hiring
Health Care
Medical Devices
As featured in
Follow
Overview
News
Technologies
Salaries
Products
People
Growth
Financials
Overview
SONIRE Therapeutics develops a next-generation ultrasound-guided high-intensity focused ultrasound (HIFU) therapy system leveraging technology and know-how originating from Tokyo Women's Medical University, Tohoku University, and Tokyo Medical University. The company designs non-invasive, radiation-free HIFU solutions intended to treat intractable cancers such as pancreatic cancer. SONIRE targets clinical and hospital markets to provide alternative therapeutic options for patients and clinicians dealing with difficult-to-treat malignancies.
News
Sonire Therapeutics Awarded $13 Million Through NEDO Deep-Tech Startups Support Program (DTSU) to Advance Global Commercialization of Pancreatic Cancer Treatment
Read more
Report
Sonire Therapeutics Closes $18 Million Series A Financing to Advance Breakthrough HIFU Therapy for Pancreatic Cancer, Expands U.S. Clinical Development
Sonire Therapeutics, a U.S. based clinical-stage medical device company, today announced $18M in Series A financing. The round was led by Santé Ventures with participation from Fast Track Initiative (FTI), Nomura SPARX Investment (Japan Growth Capital Inv
Read more
Report